Related references
Note: Only part of the references are listed.A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis
Gregg S. Wilkinson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease
Colin R. Dunstan et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
Mark J. Clemons et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular mechanisms of action of bisphosphonates: Current status
Anke J. Roelofs et al.
CLINICAL CANCER RESEARCH (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management
Salvatore L. Ruggiero et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2006)
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
M. Botteman et al.
ANNALS OF ONCOLOGY (2006)
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years
V Guarneri et al.
ONCOLOGIST (2005)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
RE Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The causes and treatment of bone loss associated with carcinoma of the breast
J Lester et al.
CANCER TREATMENT REVIEWS (2005)
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
HL Neville-Webbe et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Anti-tumour activity of zoledronic acid
P Clezardin
CANCER TREATMENT REVIEWS (2005)
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
SD Reed et al.
JOURNAL OF UROLOGY (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases
SL Ruggiero et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2004)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
